Disease-Focused Next Generation Sequencing (NGS)
As evidence-based personalized medicine displaces empiric approaches to the treatment and management of many cancers, whether through targeted therapeutics or onco-immunologics, next generation sequencing is critical to unlocking the power of the patient personal genome and delivering more, and better, insights into disease.
The value of this highly sensitive and rapid technology is evident in disease diagnosis and risk stratification, detection of minimal residual disease (MRD), detection of response or resistance to therapy, and detection of disease re-emergence and disease evolution.
Cytogenetics (Karyotyping and FISH)
Detection of cytogenetic anomalies by traditional G-banding/chromosome analysis or fluorescent in situ hybridization (FISH) can provide diagnostic and prognostic information and risk stratification for better patient management and even treatment decisions and response.
With the possible exception of advanced molecular techniques, only flow cytometry can provide the wealth of phenotypic information required for diagnosis of the most complex hematopoietic malignancies and disorders. siParadigm's ten-color flow interrogation reduces specimen requirements and cost, all while delivering exceptionally efficient turnaround times.
Our hematopathologists are expert morphologists; a thorough understanding of the subtleties of cell architecture and pattern recognition means our integrated reporting is rooted in classic techniques married with state-of-the-art equipment and an extensive suite of immunohistochemical and special stains.
siPortfolio Correlated Reporting
Taken on their own, results from individual technologies can survey a number of disease attributes, but a complete patient picture or dossier is dependent on expert selection of medically-appropriate technologies and a clinicopathologic correlation that gives information to diagnose, stratify, and treat in one place.